News | March 24, 2025
AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
FlexiTubes will showcase range of eco-friendly and innovative tube options
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
Subscribe To Our Newsletter & Stay Updated
